Antoinette R Tan, MD

The Cancer Institute of New Jersey (CINJ) 195 Little Albany Street, Room 4509 New Brunswick, NJ 08901 tanan@umdnj.edu

Clinical Specialty: Medical Oncology - Breast Cancer and Phase I

Degree

• MHSc from Duke University School of Medicine
• MD from UMDNJ-Robert Wood Johnson Medical School
• BA from Rutgers University

Grants

• Targeting the Vascular Endothelial Growth Factor Receptor in Early Stage Breast Cancer (American Society of Clinical Oncology)

Honors

• Merit Award
  ASCO (2003)
• Graduate Highest Honors
  Rutgers College (1993)
• Dean's List
  Rutgers College (1993)

Society

• American Society of Clinical Oncology (2006 - 2009)
• American Association for Cancer Research (2006 - 2009)
• American College of Physicians (2001 - 2009)

Publications

• Tan AR, Rubin EH, Vamos DC, Shuster DE, Wong YN, Fang F, Ashworth S, and Rosen LS Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res . 2009; 15:4213.
• Fetterly GJ, Grasela TH, Sherman JW, Dul JL, Grahn A, Lecomte D, Fiedler-Kelly J, Damjanov N, Fishman M, Kane MP, Rubin EH, Tan AR Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel Clin Cancer Res. 2008; 14:5856.
• Tan AR and Swain SM Ongoing Adjuvant Trials with Trastuzumab (Herceptin) in Breast Cancer Semin Oncol. 2003; 30:54.
• Tan AR and Swain SM Adjuvant Chemotherapy for Breast Cancer: An Update Semin Oncol. 2001; 28:359.
• Tan AR and Swain SM Novel Agents: Clinical Trial Design. Semin Oncol. 2001; 28:148.
• Tan AR, Steinberg SM, Parr AL, Nguyen D, and Yang S Markers in the Epidermal Growth Factor Receptor Pathway and Skin Toxicity during Erlotinib Treatment. Ann Oncol . 2008; 19:185.
• Tan AR, Moore DF, Hidalgo M, Doroshow JH, Poplin EA, Goodin S, Mauro D, and Rubin EH Pharmacokinetics of Cetuximab after Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors Clin Cancer Res. 2006; 12:6517.
• Yang SX, Simon R, Tan AR, Nguyen D, and Swain SM Gene Expression Patterns and Profile Changes Pre- and Post-Erlotinib Treatment in Patients with Metastatic Breast Cancer Clin Cancer Res . 2005; 11:6226.
• Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, and Swain SM Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer Clin Cancer Res. 2004; 10:5038.
• Tan AR, Yang X, Hewitt S, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, and Swain SM Evaluation of Biologic End Points and Pharmacokinetics in Patients with Metastatic Breast Cancer after Treatment with Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor J Clin Oncol. 2004; 22:3080.
• Lepper ER, Swain SM, Tan AR, Figg WD, and Sparreboom A Liquid-Chromatographic Determination of Erlotinib (OSI-774), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Chromatogr B Analyt Technol Biomed Life Sci . 2003; 796:181.
• Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, and Senderowicz AM Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients with Advanced Neoplasms J Clin Oncol . 2002; 20:4074.

Research

• Novel targets in the treatment of breast cancer, innovative clinical trial designs, anti-angiogenic strategies, triple-negative breast cancer